NICE recommends olaparib for advanced breast cancer in final draft guidance

The National Institute for Health and Care Excellence (NICE) has recommended olaparib (Lynparza; AstraZeneca) for treatment of HER2-negative locally advanced or metastatic breast cancer in adults with BRCA1 or BRCA2 gene mutations who have had chemotherapy. In the final draft guidance, published on 9 January 2025, NICE said around 1,200 people could benefit from the […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.343160
Primary Topic: Economic and Financial Impacts of Cancer
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends olaparib for advanced breast cancer in final draft guidance

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Economic and Financial Impacts of Cancer

article

NICE recommends olaparib for advanced breast cancer in final draft guidance

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Good health and well-being

Openalex Percentile: Top 99%

Economic and Financial Impacts of Cancer

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends olaparib for advanced breast cancer in final draft guidance · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS